Lifebit launches fund to help LMIC research groups win grants

Lifebit has launched an Impact Fund to help lower-income-country health organizations and research groups build secure data infrastructure and compete for grants. The move follows a new Lancet Oncology Commission calling for more genomic research to include data from low- and middle-income countries.

Why it matters: - The fund targets a grant-funding trap facing health research organizations in low- and middle-income countries and other under-resourced settings. - Lifebit is offering infrastructure, support and time-limited access to its platform so groups can produce early results that may help unlock future funding. - The initiative is designed to expand the use of existing patient, trial, registry and genomic data that may otherwise stay unused.

What happened: - Lifebit launched an Impact Fund on Oct. 8, 2026. - The company said the fund is meant to remove technical and financial barriers that keep nonprofits and health research organizations from securing research grants. - The launch follows a new Lancet Oncology Commission calling for data from LMICs to be brought into genomic research. - The Commission cites Lifebit as an example of how cloud-based platforms can widen LMIC participation in global cancer research.

The details: - Selected organizations get free access to Lifebit's Trusted Research Environment for three to 12 months. - The platform lets approved researchers analyze sensitive health data while the data stays in the organization’s own cloud environment. - Lifebit says that setup avoids security risks tied to moving patient information. - Recipients also get expert support to standardize data, build analytical workflows and connect research sites. - When the fund ends, recipients keep the results, harmonized data and workflows. - Organizations are not required to continue on Lifebit's platform after the fund period ends. - Applications close on 31 Dec. 2026. - Applications are reviewed on a rolling basis. - Decisions are made within 14 business days. - There is no cost to apply. - More information is available in the company’s announcement. - Applicants can also email grants@lifebit.ai.

Between the lines: - The Lancet Oncology Commission says genomic studies and clinical trials remain concentrated in high-income countries and among people of predominantly European ancestry. - Of nearly 48,000 registered biomarker-based cancer trial locations worldwide between 1999 and 2025, only 2% were in LMICs, compared with 81% in high-income countries. - Because genomic reference data skews European, patients of other ancestries are more likely to receive genetic results of uncertain significance and less likely to receive results that point to a treatment. - Lifebit’s pitch is that under-represented regions already hold valuable data, but need infrastructure to turn it into fundable research output. - The company frames the problem as a “chicken-and-egg” cycle: funders want results first, but results require secure systems and staff.

What’s next: - Lifebit will review applications on a rolling basis through the end of 2026. - The first funded organizations will use the platform and support package to build pilot results and research workflows. - The longer-term goal is for those groups to keep using the harmonized data and workflows after the fund period ends.

The bottom line: - Lifebit is betting that modest upfront support can help LMIC research groups cross the early funding gap and compete more effectively for grants.